SCHEDULE 13G: ADAR1 Entities Disclose 9.99% Stake in Inhibikase Therapeutics
Beneficial Ownership Disclosure
ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.99% of Inhibikase Therapeutics, Inc.'s common stock.
Summary
- ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger have jointly filed a Schedule 13G with the SEC regarding their beneficial ownership in Inhibikase Therapeutics, Inc.
- Each of the reporting persons or entities beneficially owns 9.99% of the outstanding common stock of Inhibikase Therapeutics, Inc.
- ADAR1 Capital Management, LLC and Daniel Schneeberger each beneficially own 6,809,355 shares, which includes 969,149 shares underlying milestone warrants as of February 7, 2025.
- ADAR1 Capital Management GP, LLC beneficially owns 6,994,246 shares, which includes 2,319,409 shares underlying milestone warrants as of February 7, 2025.
- The beneficial ownership percentages are calculated based on 67,192,570 shares of Inhibikase Therapeutics, Inc. common stock reported outstanding as of November 1, 2024.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing (Schedule 13G) disclosing beneficial ownership. It contains no subjective language, forward-looking statements, or performance data that would indicate a positive or negative sentiment.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant passive investment by ADAR1 Capital Management entities in Inhibikase Therapeutics, Inc., a company operating in the biotechnology sector. Such filings are routine disclosures for investors crossing certain ownership thresholds and do not inherently provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The disclosure of a significant 9.99% stake by ADAR1 Capital Management entities could be viewed positively by some investors as a vote of confidence, while others might monitor for potential future changes in investment strategy or influence.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which 67,192,570 shares of Common Stock of Inhibikase Therapeutics, Inc. were reported outstanding in the Issuer's Quarterly Report on Form 10-Q. |
| 2024-11-14 | Date the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, was filed with the SEC. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership threshold met/crossed). |
| 2025-02-07 | Date as of which specific share counts, including shares underlying milestone warrants, were calculated for beneficial ownership. |
| 2025-02-14 | Date the Joint Filing Agreement was executed and the Schedule 13G was signed. |
Keywords
Inhibikase Therapeutics Inc., ADAR1 Capital Management LLC, ADAR1 Capital Management GP LLC, Daniel Schneeberger, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.